Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Study of Outcome After Discontinuation of Risperidone Long-Acting Injection in First-Episode Schizophrenia
2015-001221-16Phase 4
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of risperidone in schizophrenia, sponsored by Janssen Pharmaceutical. Primary endpoint: Time to relapse after discontinuation of RLAI.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2015-001221-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001221-16.